The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Trailblazer Award for New and Early Stage Investigators, aimed at fostering creative biomedical research that integrates engineering with life sciences. This funding opportunity, under the R21 Exploratory/Developmental Research Grant mechanism, allows up to $400,000 in direct costs over three years for projects with minimal preliminary data. Applicants must be classified as NIH-defined New or Early Stage Investigators and are encouraged to propose high-risk, high-reward research that challenges existing paradigms without the need for extensive preliminary data, which may be provided but should be limited. Key dates include an open submission date of January 16, 2025, and an expiration date of January 8, 2026. Eligible organizations may consist of various educational and nonprofit institutions. The review process will focus on the significance, innovation, rigor, and feasibility of proposed research. The award seeks to enhance diversity within the research community, encouraging applications from underrepresented groups. Overall, this initiative reflects NIH’s commitment to advancing innovative research approaches that have the potential to transform fields in biomedical science.